Leerink Partners Begins Coverage on Medpace (NASDAQ:MEDP)

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating and a $330.00 target price on the stock.

Separately, Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Stock Up 2.0 %

Medpace stock opened at $330.59 on Monday. The business has a 50-day simple moving average of $337.29 and a 200 day simple moving average of $339.65. Medpace has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, research analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MEDP. Pallas Capital Advisors LLC grew its position in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Barclays PLC raised its stake in shares of Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after purchasing an additional 844 shares during the period. Loomis Sayles & Co. L P grew its stake in shares of Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock worth $68,696,000 after purchasing an additional 13,880 shares during the last quarter. Finally, Cerity Partners LLC raised its position in Medpace by 18.7% during the 3rd quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock valued at $20,659,000 after purchasing an additional 9,741 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.